Search

Your search keyword '"Braunwald, Eugene"' showing total 485 results

Search Constraints

Start Over You searched for: Author "Braunwald, Eugene" Remove constraint Author: "Braunwald, Eugene" Database Complementary Index Remove constraint Database: Complementary Index
485 results on '"Braunwald, Eugene"'

Search Results

3. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications.

5. Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial.

6. Cardio-obstetrics: a new specialty.

7. Cardiovascular effects of climate change.

8. Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis.

10. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation.

11. Natriuretic peptides, body mass index and heart failure risk: Pooled analyses of SAVOR‐TIMI 53, DECLARE‐TIMI 58 and CAMELLIA‐TIMI 61.

12. Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial.

13. Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

14. Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.

15. Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes.

16. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF.

17. Triglycerides: the past, the present, and the future.

18. Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillation.

19. Diabetocardiology: a new subspecialty?

20. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis.

21. A polygenic risk score predicts atrial fibrillation in cardiovascular disease.

22. Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54.

24. Atrial amyloidosis: mechanisms and clinical manifestations.

25. Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial.

27. Air pollution: challenges and opportunities for cardiology.

28. Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win‐ratio analysis of the PARADISE‐MI trial.

30. Association of Apolipoprotein B–Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

32. Short interfering RNA: a rapidly developing drug class.

33. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.

34. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.

36. Inhibition of angiotensinogen in the treatment of hypertension.

40. Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial.

41. Leaders in cardiovascular research: Eugene Braunwald.

42. Heart failure: a 70 year Odyssey.

43. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.

Catalog

Books, media, physical & digital resources